CDER Pilot Program Offers Potential New Pathway For Approval Of Novel Pharmaceutical Excipients
After decades without an approval pathway for excipients, FDA pilot program paves the way for innovation.
You may also be interested in...
The FDA’s proposal to establish a separate review path for novel excipients draws industry plaudits and requests for fine-tuning.
Proposal could yield a bounty of new options for innovative drug delivery systems.
Individuals from pharma, biotech, technology and academia create shared database to facilitate development of therapeutic proteins that are unlikely to provoke immune reactions.